Unlock instant, AI-driven research and patent intelligence for your innovation.

Pharmaceutical composition for preventing and treating polycystic ovarian syndrome and application thereof

A technology for polycystic ovary and a composition, applied in the field of medicine, can solve the problem that the effect of polycystic ovary syndrome needs to be improved, and achieve the effect of improving polycystic ovary syndrome and reversing insulin resistance

Active Publication Date: 2022-05-13
HEILONGJIANG UNIV OF CHINESE MEDICINE
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] However, the current active ingredients obtained from Shaoyao Gancao Decoction that can be used in the treatment of polycystic ovary syndrome still need to be further verified through experiments, and the effect of a single active ingredient in the treatment of polycystic ovary syndrome also needs to be improved

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for preventing and treating polycystic ovarian syndrome and application thereof
  • Pharmaceutical composition for preventing and treating polycystic ovarian syndrome and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Three-week-old SD rats were selected to prepare polycystic ovary syndrome insulin resistance animal models, and drug intervention was performed on the successful model mice.

[0024] ELISA and other methods were used for detection, and statistical software SPSS 22.0 was used for analysis to clarify the synergistic therapeutic effect and possible mechanism of the pharmaceutical composition of the embodiment of the present invention on polycystic ovary syndrome insulin resistance animal models.

[0025] 1. Materials

[0026] 1.1 Experimental animals

[0027] 120 3-week-old SPF female SD rats were raised in the Animal Center of the First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine. 25°C constant temperature (50% humidity) clean-grade breeding, without feeding vitamin products, 12h light and 12h dark cycle alternately.

[0028] 1.2 Main reagents

[0029] DHEA (Sigma Company), formononetin and isoliquiritigenin were extracted from Shaoya...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a pharmaceutical composition for preventing and treating polycystic ovarian syndrome and application of the pharmaceutical composition. The active ingredient of the pharmaceutical composition is a combination of formononetin and isoliquiritigenin. The pharmaceutical composition disclosed by the invention can be used for improving the polycystic ovarian syndrome in a synergistic manner, and particularly can be used for regulating sexual cycle disorder caused by the polycystic ovarian syndrome in a synergistic manner and reversing insulin resistance in a synergistic manner.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a medicine for treating polycystic ovary syndrome, in particular to a pharmaceutical composition for preventing and treating polycystic ovary syndrome and its application. Background technique [0002] Polycystic ovary syndrome (PCOS) is a common complex endocrine and metabolic disorder in women of childbearing age. ) is characterized by irregular menstrual cycles, infertility, hirsutism and / or acne, and is the most common female endocrine disease. [0003] At present, drug treatment of PCOS has replaced surgical treatment as the first-line treatment, and the purpose of treatment is mainly related to the fertility requirements of patients. Oral contraceptives (OCP) have been used as a traditional long-term treatment for women with PCOS, mainly used to protect the endometrium, adjust the menstrual cycle, and improve hirsutism and / or acne by reducing the androgen prod...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/352A61P15/08A61P5/50A61K31/12
CPCA61K31/352A61K31/12A61K9/0019A61P15/08A61P5/50A61K2300/00
Inventor 常惠文雁
Owner HEILONGJIANG UNIV OF CHINESE MEDICINE